Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular ...

Materials & Methods: The NDS consisted of cationic liposomes (carrier, 100–140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing University, Hongkai Bi at Hainan Medical University, Hong Ling at Harbin ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...